Inge E Deckers1, Farida Benhadou2, Marjolein J Koldijk3, Veronique Del Marmol2, Barbara Horváth3, Jurr Boer4, Hessel H van der Zee1, Errol P Prens5. 1. Department of Dermatology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands. 2. Department of Dermatology, Hôpital Erasme, Université Libre de Bruxelles, Bruxelles, Belgium. 3. Department of Dermatology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands. 4. Department of Dermatology, Deventer Hospital, Deventer, The Netherlands. 5. Department of Dermatology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands. Electronic address: e.prens@erasmusmc.nl.
Abstract
BACKGROUND: Hidradenitis suppurativa (HS) is often associated with inflammatory bowel disease (IBD; Crohn's disease or ulcerative colitis). However, the prevalence of IBD in HS patients is unknown. OBJECTIVE: To determine the prevalence of IBD in HS patients, and determine if patients with HS and IBD have a distinct HS phenotype. METHODS: For this multicenter, cross-sectional study, HS patients were asked during their first consultation if they had IBD. The diagnosis of IBD was checked in the medical files, and clinical characteristics were collected. RESULTS: IBD had a prevalence of 3.3% (95% CI 2.3-4.4) in 1076 HS patients. The prevalence of Crohn's disease was 2.5% (95% CI 1.6-3.4) and the prevalence of ulcerative colitis was 0.8% (95% CI 0.3-1.4). HS-IBD patients were less frequently obese (13.9% vs 31.2%, P = .04) than HS-only patients, but there were no differences in gender, family history of HS, disease severity, body areas affected by HS, or smoking status. LIMITATIONS: The prevalence might be underestimated since HS patients might still develop IBD. CONCLUSION: The prevalence of IBD in HS patients (3.3%) is 4-8 times higher than the prevalence in the general northern European population (0.41%-0.74%), however HS-IBD patients do not have a distinct HS phenotype.
BACKGROUND:Hidradenitis suppurativa (HS) is often associated with inflammatory bowel disease (IBD; Crohn's disease or ulcerative colitis). However, the prevalence of IBD in HSpatients is unknown. OBJECTIVE: To determine the prevalence of IBD in HSpatients, and determine if patients with HS and IBD have a distinct HS phenotype. METHODS: For this multicenter, cross-sectional study, HSpatients were asked during their first consultation if they had IBD. The diagnosis of IBD was checked in the medical files, and clinical characteristics were collected. RESULTS: IBD had a prevalence of 3.3% (95% CI 2.3-4.4) in 1076 HSpatients. The prevalence of Crohn's disease was 2.5% (95% CI 1.6-3.4) and the prevalence of ulcerative colitis was 0.8% (95% CI 0.3-1.4). HS-IBDpatients were less frequently obese (13.9% vs 31.2%, P = .04) than HS-only patients, but there were no differences in gender, family history of HS, disease severity, body areas affected by HS, or smoking status. LIMITATIONS: The prevalence might be underestimated since HSpatients might still develop IBD. CONCLUSION: The prevalence of IBD in HSpatients (3.3%) is 4-8 times higher than the prevalence in the general northern European population (0.41%-0.74%), however HS-IBDpatients do not have a distinct HS phenotype.
Authors: R Sabat; A Tsaousi; J Rossbacher; H Kurzen; T Fadai; U Schwichtenberg; S Schneider-Burrus; G Kokolakis; K Wolk Journal: Hautarzt Date: 2017-12 Impact factor: 0.751
Authors: Jacob Wiseman; Tanya Chawla; Frederic Morin; Anthony de Buck van Overstraeten; Adam V Weizman Journal: Clin Colon Rectal Surg Date: 2022-01-17
Authors: Gautham Vellaichamy; Peter Dimitrion; Li Zhou; David Ozog; Henry W Lim; Wilson Liao; Iltefat H Hamzavi; Qing-Sheng Mi Journal: J Invest Dermatol Date: 2021-04-07 Impact factor: 7.590
Authors: Robert W Dunstan; Katherine M Salte; Viktor Todorović; Margaret Lowe; Joseph B Wetter; Paul W Harms; Richard E Burney; Victoria E Scott; Kathleen M Smith; Michael D Rosenblum; Johann E Gudjonsson; Prisca Honore Journal: Exp Dermatol Date: 2021-01-20 Impact factor: 3.960